VERADERMICS INC

MANENYSE

🏆 #1354 by market capEarnings Nov 10US Equity

$117.80▲ $3.05 (+2.59%)

After hours · at close

🔔

Track MANE

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 2.6%

7d▼ 0.2%

14d▲ 13.3%

30d▲ 20.8%

ytd—

1y—

🏦Market Cap

$4.92B

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $117.22 – $119.39
52-Week Range: $32.00 – $131.24
Volume: $2.76B
Avg Volume: $3.08B
Shares Outstanding: 41.8M
Next Earnings: Nov 18, 2026

Fundamentals Snapshot

Annual Revenue: $684M
Last Q Revenue: $154M
P/E Ratio: -53.4
P/S Ratio: 0.0x
EPS (TTM): $-2.29
Dividend Yield: 0.00%
Dilution (1yr): −81.5%

Why Investors Own MANE

✓High-growth profile — revenue up -4.2% YoY with expanding US Equity exposure.
✓Healthy economics — 51% gross margin and 7% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

VERADERMICS INC

MANE

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$72M▲ +170.2% YoY

Free Cash Flow

−$72M▲ +202.4% YoY

Shares Outstanding

37.3M▼ −81.5% YoY

Net Cash

$22M▼ −$31M YoY

StockOtter · stockotter.space

About VERADERMICS INC

Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.

🦦